sunitinib mylan 12,5 mg
remedica ltd - cipru - sunitinibum - caps. - 12,5mg - alte antineoplazice inhibitori de protein-kinaza
sunitinib mylan 25 mg
remedica ltd - cipru - sunitinibum - caps. - 25mg - alte antineoplazice inhibitori de protein-kinaza
sunitinib mylan 37,5 mg
remedica ltd - cipru - sunitinibum - caps. - 37,5mg - alte antineoplazice inhibitori de protein-kinaza
sunitinib mylan 50 mg
remedica ltd - cipru - sunitinibum - caps. - 50mg - alte antineoplazice inhibitori de protein-kinaza
sunitinib viatris 12,5 mg
remedica ltd - cipru - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 25 mg
remedica ltd - cipru - sunitinibum - caps. - 25mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 37,5 mg
remedica ltd - cipru - sunitinibum - caps. - 37,5mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib viatris 50 mg
remedica ltd - cipru - sunitinibum - caps. - 50mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib teva 12,5 mg
teva operations poland sp. z.o.o - polonia - sunitinibum - caps. - 12,5mg - inhibitori de protein-kinaza